BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• 

  Business

  J&J, Emergent Accuse Each Other Of Violating COVID-19 Vaccine Deal

  Johnson & Johnson and Emergent BioSolutions are accusing each other of breaching their COVID-19 vaccine supply agreement.

  June 7, 2022

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Drug Development

  Novartis Combo could be New Standard of Care for Pediatric Glioma Patients

  Results of a Phase II/III study showed that patients who were given Tafinlar plus Mekinist saw an overall response rate of 47% vs. 11% for those who received standard chemotherapy only.

  June 7, 2022

   · 

  3 min read

   · 

  Tristan Manalac
• 

  Business

  Sernova Cell Pouch Keeps T1 Diabetes Patient Insulin Free for 2 Years

  Sernova shared positive Phase I/II data from an ongoing clinical study of its implantable Cell Pouch device that showed evidence of in vivo active insulin production.

  June 7, 2022

   · 

  4 min read

   · 

  Alex Keown
• 

  Drug Development

  CEL-SCI, Jazz, CARsgen, Ascentage and Portage Showcase New Data at ASCO

  CEL-SCI Corporation, Jazz Pharmaceuticals, CARsgen and Ascentage Pharma presented clinical trial data at the American Society of Clinical Oncology 2022 Annual Meeting.

  June 7, 2022

   · 

  4 min read

   · 

  Mark Terry
• 

  Business

  Bayer Oncology Leaders Fueling Ambitious 2030 “Top 10” Target

  BioSpace caught up with Tara Frenkl and Nelson Ambrogio ahead of ASCO to discuss Bayer’s goal of becoming a top 10 oncology company by 2030.

  June 7, 2022

   · 

  6 min read

   · 

  Heather McKenzie
• 

  Policy

  Novartis Latest Target in Cyberattack Extortion Plot

  Novartis has fallen victim to a cyberattack. The Swiss pharma giant’s data was hijacked by a well-known online extortion ring dubbed Industrial Spy.

  June 7, 2022

   · 

  2 min read

   · 

  Alex Keown
• 

  Drug Development

  Eli Lilly’s Phase III Atopic Dermatitis Drug Touts Significant Skin Clearance

  The Phase III ADvocate 1 and 2 studies on lebrikizumab showed that eight out of 10 patients with atopic dermatitis maintained skin clearance in the 12 months they had been under treatment.

  June 7, 2022

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Drug Development

  Merck Predicts Over 80 Potential Oncology Approvals Through 2028

  Powered by its blockbuster checkpoint inhibitor Keytruda, Merck is forecasting a potential of more than 80 new regulatory approvals in oncology through 2028.

  June 7, 2022

   · 

  3 min read

   · 

  Alex Keown
• 

  Drug Development

  Lilly’s Mounjaro Bests Novo’s Diabetes Drugs in Comparison Study

  The Phase I mechanism of action study, showing that Lilly’s injectable Mounjaro (tirzepatide) induces greater weight loss than placebo and Novo Nordisk’s semaglutide in adults with type 2 diabetes.

  June 7, 2022

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Drug Development

  Seres Touts Strong Phase III Results Against Recurrent C. Difficile Infection

  Seres Therapeutics, Inc. announced that the company’s Phase III Ecospor IV study demonstrated a strong safety profile in addition to statistically significant positive results against C. difficile infection.

  June 7, 2022

   · 

  2 min read

   · 

  Jazmine Colatriano, M.S.